Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05376592 · ClinicalTrials.gov registry record
Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
A clinical trial of Cachexia and Pancreas Adenocarcinoma, sponsored by Wake Forest University Health Sciences.
- Recruiting
- Registry status
- 100
- Enrollment target
- 2
- Study locations
NCT05376592 is a study of Cachexia and Pancreas Adenocarcinoma that is actively recruiting participants, run by Wake Forest University Health Sciences. The registered enrollment target is 100 participants, below the 194-participant average among 13 other Cachexia trials with a reported enrollment target (48% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05376592, a study of Cachexia and Pancreas Adenocarcinoma, is actively recruiting participants, sponsored by Wake Forest University Health Sciences.
- RECRUITING
- Registry status
- 100 participants
- Enrollment target
- 2
- Study locations
Study Summary
A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occur in over 75% of patients with advanced PDAC, the highest incidence of all solid tumors, and contributes significantly to poor outcomes and mortality. Though there is overlap amongst the pathophysiologic studies evaluating CC in murine models of different tumor types, the high prevalence of CC within gastrointestinal (GI) malignancies and specifically PDAC suggest that dedicated studies evaluating polymorphisms in candidate genes specific to PDAC warrant further evaluation. The collection and analysis of specimens under this study will facilitate the identification and characterization of genomic polymorphisms associated with CC in PDAC patients. Subsequently, this data may help contribute towards diagnostic and therapeutic treatments that may improve patient outcomes.
Conditions Studied
Study Locations (2)
North Carolina
- Levine Cancer Institute - Charlotte
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2022-06-17 |
| Est. Completion | 2031-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05376592
The ClinicalTrials.gov registry entry for NCT05376592 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 194-participant average among 13 other Cachexia trials with a reported enrollment target (48% lower). The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cachexia appearing as the primary indexed condition, and to 0 interventions.
NCT05376592 reports 2 study locations spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT05376592 about?
NCT05376592 is a clinical study titled "Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma". A major complication of pancreatic adenocarcinoma (PDAC) is cancer cachexia (CC) which is a complex syndrome characterized by skeletal muscle mass loss (with or without loss of fat mass) and progressive functional impairment not reversible by conventional nutritional support. It is estimated to occu...
What is the current status of trial NCT05376592?
This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2022-06-17. Estimated completion is 2031-01.
What conditions does trial NCT05376592 study?
This clinical trial studies the following conditions: Cachexia, Pancreas Adenocarcinoma.
Who is sponsoring clinical trial NCT05376592?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05376592 being conducted?
This trial has 2 study locations across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cachexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
RECRUITING · Phase 2
-
A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia
RECRUITING · Phase 1
-
Ruxolitinib for Cancer Cachexia
ACTIVE NOT RECRUITING · Early Phase 1
-
Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)
COMPLETED · Phase 2
-
Docetaxel With or Without Infliximab in Treating Weight Loss, Loss of Appetite, and Fatigue in Patients With Unresectable Non-Small Cell Lung Cancer (Infliximab Treatment Discontinued Effective 10/05/05)
COMPLETED · Phase 3
-
A Study Comparing Megestrol Acetate at 800 mg/Day, and Placebo in AIDS Patients With Anorexia and Cachexia
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.